Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I²-PORT for Resected Non-Small Cell Lung Cancer
NCT07293247Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Disease-Free Survival at 5 years and Incidence of late grade >= 3 cardiopulmonary toxicities at 24 months. Started Oct 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07293247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293247.